Last reviewed 2026-04-23 · How we verify

Imatinib tablets

Tyrosine kinase inhibitor

Tyrosine kinase inhibitor Used for Chronic myeloid leukemia, Acute lymphoblastic leukemia.

At a glance

Mechanism of action

Imatinib specifically inhibits the BCR-ABL tyrosine kinase, which is a product of the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL).

Approved indications

• Chronic myeloid leukemia
• Acute lymphoblastic leukemia

Common side effects

• Myelosuppression
• Nausea
• Diarrhea
• Fatigue
• Musculoskeletal pain

Key clinical trials

• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
• Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (PHASE2)
• Trial of Imatinib for Hospitalized Adults With COVID-19 (PHASE3)
• Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor (PHASE1)
• Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (PHASE2)
• A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
• Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia (PHASE2)
• A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.